Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | VNN1 | O95497 | 1/20 | 0.32 |
| ▸ | TYRO3 | Q06418 | 2/20 | 0.31 |
| ▸ | MERTK | Q12866 | 2/20 | 0.31 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.31 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.31 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.31 |
| ▸ | KDM5A | P29375 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13090386 | 1.00 | VNN1 (0.32) | VNN1TYRO3MERTKTRPV1HCRTR1 | |
| SCHEMBL13090384 | 1.00 | VNN1 (0.32) | VNN1TYRO3MERTKTRPV1HCRTR1 | |
| SCHEMBL13090383 | 1.00 | VNN1 (0.32) | VNN1TYRO3MERTKTRPV1HCRTR1 | |
| SCHEMBL13090385 | 1.00 | VNN1 (0.32) | VNN1TYRO3MERTKTRPV1HCRTR1 | |
| SCHEMBL3069145 | 0.92 | TRPV1 (0.33) | VNN1TYRO3MERTKTRPV1 | |
| SCHEMBL3076055 | 0.92 | VNN1 (0.32) | VNN1TYRO3MERTKTRPV1 | |
| SCHEMBL3064181 | 0.92 | VNN1 (0.32) | VNN1TYRO3MERTKTRPV1 | |
| SCHEMBL3068177 | 0.92 | VNN1 (0.32) | VNN1TYRO3MERTKTRPV1 | |
| SCHEMBL13256743 | 0.92 | TRPV1 (0.33) | VNN1TYRO3MERTKTRPV1 | |
| SCHEMBL3069151 | 0.92 | TRPV1 (0.33) | VNN1TYRO3MERTKTRPV1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100272680-A1 | Piperidinyl Cyclic Amido Antiviral Agents | BASKARAN SUBRAMANIAN | 2010-10-28 | — | — | US | claimed |
| WO-2010091411-A1 | PIPERIDINYL CYCLIC AMIDO ANTIVIRAL AGENTS | GLAXOSMITHKLINE LLC (US) | 2010-08-12 | — | — | WO | claimed |
| US-20100272680-A1 | Piperidinyl Cyclic Amido Antiviral Agents | BASKARAN SUBRAMANIAN | 2010-10-28 | — | — | US | disclosed |
| US-20100272680-A1 | Piperidinyl Cyclic Amido Antiviral Agents | BASKARAN SUBRAMANIAN | 2010-10-28 | — | — | US | disclosed |
| WO-2010091411-A1 | PIPERIDINYL CYCLIC AMIDO ANTIVIRAL AGENTS | GLAXOSMITHKLINE LLC (US) | 2010-08-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100272680-A1 | Piperidinyl Cyclic Amido Antiviral Agents | ZC3HAV1, MAVS, EIF2AK2 | VNN1 1145/4885TYRO3 3671/4885MERTK 2693/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.